Liver function may change how MCI-186 acts in the body

NCT ID NCT03289234

Completed Knowledge-focused Sponsor: Shionogi Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 16, 2026 · Updated 3 times

Summary

This study looked at how the drug MCI-186 (also called edaravone) behaves in people with mild or moderate liver impairment compared to those with healthy livers. Twenty-two participants received a single dose of the drug. The goal was to see if liver problems affect how the drug is processed, which could help guide future dosing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MCI-186 (edaravone)
What this could lead to: If successful, this study could help determine safe dosing of edaravone for patients with liver impairment.
What could go wrong: This is a small, early-phase study focused on drug processing, not treatment effects. Results may not apply to broader populations or predict real-world outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY HEPATIC IMPAIRMENT

Contacts and locations

Show contact details

Locations

Investigational site

Fukuoka, Japan
Investigational site

Tokyo, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.